After more than 20 years of development, bioresorbable coronary stents are close to commercialization, setting up what is sure to be a hotly contested battle for a multi-billion dollar market.
One of the key players is the Absorb bioresorbable vascular scaffold (BVS) that restores blood flow by opening a blocked artery and providing support to the vessel until the device dissolves. Once in place, Absorb dissolves in approximately two years, leaving patients with a treated vessel free of a permanent metallic implant, according to Abbott Laboratories (Abbott Park, IL).
"Absorb represents the best in scientific innovation, as it has the potential to change the way physicians practice medicine and improve outcomes for their patients," says Robert B. Hance, senior vice president, vascular, Abbott.
Absorb is being evaluated in more than 40 clinical centers in 20 countries around the world. Earlier this year, Absorb received the CE Mark in Europe for the treatment of coronary artery disease. In the United States, Absorb currently is under development and is not available for sale....